CN106366112A - Dibutylstannylfuran formate complex with heterocyclic oxotin structure, and preparation method and application thereof - Google Patents
Dibutylstannylfuran formate complex with heterocyclic oxotin structure, and preparation method and application thereof Download PDFInfo
- Publication number
- CN106366112A CN106366112A CN201610671064.3A CN201610671064A CN106366112A CN 106366112 A CN106366112 A CN 106366112A CN 201610671064 A CN201610671064 A CN 201610671064A CN 106366112 A CN106366112 A CN 106366112A
- Authority
- CN
- China
- Prior art keywords
- stannum
- furancarboxylic acid
- acid ester
- oxa
- dibutyl tin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a dibutylstannylfuran formate complex with a heterocyclic oxotin structure, and a preparation method and application thereof. The complex has a structural formula (I) as defined in the specification. R in the formula (I) represents a n-butyl group. The invention also discloses the preparation method for the dibutylstannylfuran formate complex with the heterocyclic oxotin structure and application of the dibutylstannylfuran formate complex to preparation of antitumor drugs.
Description
Technical field
The present invention relates to a kind of dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure, and preparation method thereof, with
And application in preparing antitumor drug for the dibutyl tin furancarboxylic acid ester of this coordination compound stannum oxa- ring structure.
Background technology
Organotin is the metallo-organic compound that a class contains sn-c key, has higher biological activity, in sterilization, kills
The fields such as worm, cancer therapy drug preparation have a wide range of applications.Existing research shows, the alkyl r in organotin is to determine
The principal element of compound anti-cancering activity height, e.g., the active anticancer of cyclohexyl, normal-butyl and phenyl tin compound is stronger, second
Base takes second place, and methyl is then almost without active anticancer.The structure of part is to the active anticancer of coordination compound and the wide spectrum of killing cancerous cell
Property also plays an important role, it is demonstrated experimentally that the biological activity of organotin carboxylate coordination compound is often than corresponding organotin
Compound is high.
Chinese patent cn101402650b discloses a kind of dibutyl tin with quinolinecarboxylic acid coordination compound in preparation treatment stomach
Apply in cancer, nasopharyngeal carcinoma, human liver cancer or leukemic medicine.
Chinese patent cn101434616b disclose a kind of dibutyl tin schiff alkali coordination compound preparation treatment gastric cancer,
Apply in nasopharyngeal carcinoma, human liver cancer or leukemic medicine.
It is to the experiment proved that the material with active anticancer based on the ester type compound that aromatic carboxylic acids are formed with dibutyl tin,
The present invention selects Dibutyltin oxide, with part furancarboxylic acid, reacts under certain condition, and synthesis has obtained to nci-h460
(human lung carcinoma cell), the stronger coordination compound of the inhibitory activity of mcf7 (people's breast adenocarcinoma cell), hepg2 (human liver cancer cell), be
Exploitation cancer therapy drug provides new way.
Content of the invention
The problem existing for above-mentioned prior art, the first object of the present invention there is provided a kind of stannum oxa- ring structure
Dibutyl tin furancarboxylic acid ester coordination compound.
The second object of the present invention is the system of the dibutyl tin furancarboxylic acid ester coordination compound providing above-mentioned stannum oxa- ring structure
Preparation Method.
3rd mesh of the present invention is the dibutyl tin furancarboxylic acid ester coordination compound providing above-mentioned stannum oxa- ring structure in preparation
Application in cancer therapy drug.
As a kind of dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure of first aspect present invention, its be as
The coordination compound of lower structural formula (i):
(i)
In formula, r represents normal-butyl.
The dibutyl tin furancarboxylic acid ester coordination compound of the stannum oxa- ring structure of the present invention divides through elementary analysiss, infrared spectrum
Analysis, nuclear magnetic resoance spectrum and x- ray single crystal structural analyses, result is as follows:
Elementary analysiss (c52h84o14sn4): theoretical value: c, 44.36；H, 6.01.Measured value: c, 44.40；H, 6.56.
ir(kbr, cm-1): 3126, 2959, 2926, 2859 v(c-h), 1638 vas(coo-), 1477 vas
(coo-), 642 v(sn-c), 464 v(sn-o).
1h nmr(cdcl3, 500 mhz), δ(ppm): 7.61, 7.12, 7.61(s, 12h, ar-h), 0.78-
1.73 (m, 72h, bu-h).
13c nmr(cdcl3, 125 mhz), δ(ppm): 163.20(coo), 147.58, 145.03, 116.63,
111.87(ar), 29.82, 27.56, 27.25, 27.11, 26.76, 26.71, 13.59, 13.56(bu).
119sn nmr(cdcl3, 186 mhz),δ(ppm): 194.21, 221.62.
The dibutyl tin furancarboxylic acid ester coordination compound of the stannum oxa- ring structure of the present invention is crystal structure, its crystallography number
According to: crystal belongs to monoclinic system, space group c2/c,a=4.4365 (3) nm,b=1.41495 (10) nm,c=2.38869 (16) nm,α=90 °,β=121.6420 (10) °,γ=90 °,z=8, v=12.7658 (15) nm3,dc= 1.465mg·m-3,μ(moka)=
1.601mm-1,f(000)=5664,1.67 ° of ＜θ25.00 ° of ＜, crystalline size: 0. 21 × 0.20 × 0.18mm,r=
0.0690,wr= 0.2016.
Being structurally characterized in that of the dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure of the present invention: exist in molecule
The sn being constituted with stannum and oxygen atom2o2Planar four-element ring, three four-membered rings condense formation four using sn-o key atom for bridgehead atom
Core stannum oxygen clusters trapezium structure, the center of middle ring is the symmetrical centre of molecule, has the three of two oxygen atoms difference bridging ladders in ladder
Individual tin atom, separately has two oxygen atoms bridging ladder tin atom respectively；It is former that the other two furan carboxyphenyls of ladder are utilized respectively its carboxyl oxygen
Son becomes the hexa-atomic stannum oxa- ring structure of bond formed and its common chain with the tin atom of sn-o-sn chain.
Preparation as a kind of dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure of second aspect present invention
Method, sequentially adds furancarboxylic acid, Dibutyltin oxide and etoh solvent in reaction vessel in order, is 50 ~ 65 in temperature
8～24h is reacted under conditions of DEG C；Cooling, filters, and controls solvent volatilization crystallization, obtain water white transparency brilliant under conditions of 20 ~ 35 DEG C
The dibutyl tin furancarboxylic acid ester coordination compound of body, as stannum oxa- ring structure.
In a preferred embodiment of the invention, the amount ratio of the material of described furancarboxylic acid, both Dibutyltin oxides
For 1:(1 ~ 1.05).
In a preferred embodiment of the invention, described etoh solvent consumption adds 20 for every mM of Dibutyltin oxide
~ 35 milliliters.
Prepared by the dibutyl tin furancarboxylic acid ester coordination compound as a kind of stannum oxa- ring structure of third aspect present invention
Application in cancer therapy drug.
Applicant has carried out anti tumor activity in vitro and has confirmed research to above-mentioned coordination compound, confirms that this coordination compound has certain
Anti-tumor biological is that is to say, that the purposes of above-mentioned coordination compound is the application in preparing antitumor drug, specifically
It is to prepare anti-human lung-cancer medicament, human breast carcinoma, the application in human liver cancer medicine.
The dibutyl tin furancarboxylic acid ester coordination compound of the stannum oxa- ring structure of the present invention to human lung cancer medicine, human breast carcinoma,
Human liver cancer medicine etc. shows good active anticancer, can be with it for raw material preparation anti-lung cancer, anti-breast cancer, medicines resistant to liver cancer.
Compared with the platinum-containing anticancer drug commonly using at present, the dibutyl tin furancarboxylic acid ester cooperation of the stannum oxa- ring structure of the present invention
Thing have active anticancer height, low cost, preparation method simple the features such as, provide new way for exploitation cancer therapy drug.
Brief description
Fig. 1 is the crystal molecular structure figure of the dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure.
Fig. 2 is the ir spectrogram of the dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure.
Fig. 3 is the dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure1H nmr spectrogram.
Fig. 4 is the dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure13C nmr spectrogram.
Fig. 5 is the dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure119Sn nmr spectrogram.
Fig. 6 is the tg-dtg curve of the dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure.
Specific embodiment
Further describe the present invention by following examples, but it should be noted that the scope of the present invention is not implemented by these
Any restriction of example.
Embodiment 1:
The preparation of the dibutyl tin furancarboxylic acid ester of stannum oxa- ring structure:
Furancarboxylic acid 0.1126g (1mmol), Dibutyltin oxide 0.2491g is sequentially added in order in 100ml round-bottomed flask
(1mmol), etoh solvent 20ml, reacts 8h under conditions of temperature is 50 ~ 65 DEG C；Cooling, filters, in 20 ~ 35 DEG C of condition
Lower control solvent volatilization crystallization, obtains colourless transparent crystal, as the dibutyl tin furancarboxylic acid ester of stannum oxa- ring structure.Yield:
73%, fusing point: 148-149 DEG C.
Elementary analysiss (c52h84o14sn4): theoretical value: c, 44.36；H, 6.01.Measured value: c, 44.40；H, 6.56.
ir(kbr, cm-1): 3126, 2959, 2926, 2859 v(c-h), 1638 vas(coo-), 1477 vas
(coo-), 642 v(sn-c), 464 v(sn-o).
1h nmr(cdcl3, 500 mhz), δ(ppm): 7.61, 7.12, 7.61(s, 12h, ar-h), 0.78-
1.73 (m, 72h, bu-h).
13c nmr(cdcl3, 125 mhz), δ(ppm): 163.20(coo), 147.58, 145.03, 116.63,
111.87(ar), 29.82, 27.56, 27.25, 27.11, 26.76, 26.71, 13.59, 13.56(bu).
119sn nmr(cdcl3, 186 mhz),δ(ppm): 194.21, 221.62.
Its crystallographic data: crystal belongs to monoclinic system, space group c2/c,a=4.4365 (3) nm,b=1.41495(10)
Nm,c=2.38869 (16) nm,α=90 °,β=121.6420 (10) °,γ=90 °,z=8, v=12.7658 (15) nm3,dc=
1.465mg·m-3,μ(moka)=1.601mm-1,f(000)=5664,1.67 ° of ＜θ25.00 ° of ＜, crystalline size: 0. 21 ×
0.20 × 0.18mm,r=0.0690,wr= 0.2016.
Embodiment 2:
The preparation of the dibutyl tin furancarboxylic acid ester of stannum oxa- ring structure:
Furancarboxylic acid 0.1118g (1mmol), Dibutyltin oxide 0.2615g is sequentially added in order in 100ml round-bottomed flask
(1.05mmol), etoh solvent 37ml, reacts 10h under conditions of temperature is 50 ~ 65 DEG C；Cooling, filters, at 20 ~ 35 DEG C
Under the conditions of control solvent volatilization crystallization, obtain colourless transparent crystal, as the dibutyl tin furancarboxylic acid ester of stannum oxa- ring structure.Produce
Rate: 74%, fusing point: 148-149 DEG C.
Elementary analysiss (c52h84o14sn4): theoretical value: c, 44.36；H, 6.01.Measured value: c, 44.40；H, 6.56.
ir(kbr, cm-1): 3126, 2959, 2926, 2859 v(c-h), 1638 vas(coo-), 1477 vas
(coo-), 642 v(sn-c), 464 v(sn-o).
1h nmr(cdcl3, 500 mhz), δ(ppm): 7.61, 7.12, 7.61(s, 12h, ar-h), 0.78-
1.73 (m, 72h, bu-h).
13c nmr(cdcl3, 125 mhz), δ(ppm): 163.20(coo), 147.58, 145.03, 116.63,
111.87(ar), 29.82, 27.56, 27.25, 27.11, 26.76, 26.71, 13.59, 13.56(bu).
119sn nmr(cdcl3, 186 mhz),δ(ppm): 194.21, 221.62.
Its crystallographic data: crystal belongs to monoclinic system, space group c2/c,a=4.4365 (3) nm,b=1.41495(10)
Nm,c=2.38869 (16) nm,α=90 °,β=121.6420 (10) °,γ=90 °,z=8, v=12.7658 (15) nm3,dc=
1.465mg·m-3,μ(moka)=1.601mm-1,f(000)=5664,1.67 ° of ＜θ25.00 ° of ＜, crystalline size: 0. 21 ×
0.20 × 0.18mm,r=0.0690,wr= 0.2016.
Embodiment 3:
The preparation of the dibutyl tin furancarboxylic acid ester of stannum oxa- ring structure:
Furancarboxylic acid 0.2247g (2mmol), Dibutyltin oxide 0.5223g is sequentially added in order in 100ml round-bottomed flask
(2.10mmol), etoh solvent 50ml, reacts 15h under conditions of temperature is 50 ~ 65 DEG C；Cooling, filters, at 20 ~ 35 DEG C
Under the conditions of control solvent volatilization crystallization, obtain colourless transparent crystal, as the dibutyl tin furancarboxylic acid ester of stannum oxa- ring structure.Produce
Rate: 73%, fusing point: 148-149 DEG C.
Elementary analysiss (c52h84o14sn4): theoretical value: c, 44.36；H, 6.01.Measured value: c, 44.40；H, 6.56.
ir(kbr, cm-1): 3126, 2959, 2926, 2859 v(c-h), 1638 vas(coo-), 1477 vas
(coo-), 642 v(sn-c), 464 v(sn-o).
1h nmr(cdcl3, 500 mhz), δ(ppm): 7.61, 7.12, 7.61(s, 12h, ar-h), 0.78-
1.73 (m, 72h, bu-h).
13c nmr(cdcl3, 125 mhz), δ(ppm): 163.20(coo), 147.58, 145.03, 116.63,
111.87(ar), 29.82, 27.56, 27.25, 27.11, 26.76, 26.71, 13.59, 13.56(bu).
119sn nmr(cdcl3, 186 mhz),δ(ppm): 194.21, 221.62.
Its crystallographic data: crystal belongs to monoclinic system, space group c2/c,a=4.4365 (3) nm,b=1.41495(10)
Nm,c=2.38869 (16) nm,α=90 °,β=121.6420 (10) °,γ=90 °,z=8, v=12.7658 (15) nm3,dc=
1.465mg·m-3,μ(moka)=1.601mm-1,f(000)=5664,1.67 ° of ＜θ25.00 ° of ＜, crystalline size: 0. 21 ×
0.20 × 0.18mm,r=0.0690,wr= 0.2016.
Embodiment 4:
The preparation of the dibutyl tin furancarboxylic acid ester of stannum oxa- ring structure:
Furancarboxylic acid 0.3357g (3mmol), Dibutyltin oxide 0.7472g is sequentially added in order in 100ml round-bottomed flask
(3mmol), etoh solvent 60ml, reacts 24h under conditions of temperature is 50 ~ 65 DEG C；Cooling, filters, in 20 ~ 35 DEG C of condition
Lower control solvent volatilization crystallization, obtains colourless transparent crystal, as the dibutyl tin furancarboxylic acid ester of stannum oxa- ring structure.Yield:
74%, fusing point: 148-149 DEG C.
Elementary analysiss (c52h84o14sn4): theoretical value: c, 44.36；H, 6.01.Measured value: c, 44.40；H, 6.56.
ir(kbr, cm-1): 3126, 2959, 2926, 2859 v(c-h), 1638 vas(coo-), 1477 vas
(coo-), 642 v(sn-c), 464 v(sn-o).
1h nmr(cdcl3, 500 mhz), δ(ppm): 7.61, 7.12, 7.61(s, 12h, ar-h), 0.78-
1.73 (m, 72h, bu-h).
13c nmr(cdcl3, 125 mhz), δ(ppm): 163.20(coo), 147.58, 145.03, 116.63,
111.87(ar), 29.82, 27.56, 27.25, 27.11, 26.76, 26.71, 13.59, 13.56(bu).
119sn nmr(cdcl3, 186 mhz),δ(ppm): 194.21, 221.62.
Its crystallographic data: crystal belongs to monoclinic system, space group c2/c,a=4.4365 (3) nm,b=1.41495(10)
Nm,c=2.38869 (16) nm,α=90 °,β=121.6420 (10) °,γ=90 °,z=8, v=12.7658 (15) nm3,dc=
1.465mg·m-3,μ(moka)=1.601mm-1,f(000)=5664,1.67 ° of ＜θ25.00 ° of ＜, crystalline size: 0. 21 ×
0.20 × 0.18mm,r=0.0690,wr= 0.2016.
Embodiment 5:
The preparation of the dibutyl tin furancarboxylic acid ester of stannum oxa- ring structure:
Furancarboxylic acid 0.3368g (3mmol), Dibutyltin oxide 0.7468g is sequentially added in order in 100ml round-bottomed flask
(3mmol), etoh solvent 70ml, reacts 24h under conditions of temperature is 50 ~ 65 DEG C；Cooling, filters, in 20 ~ 35 DEG C of condition
Lower control solvent volatilization crystallization, obtains colourless transparent crystal, as the dibutyl tin furancarboxylic acid ester of stannum oxa- ring structure.Yield:
73%, fusing point: 148-149 DEG C.
Elementary analysiss (c52h84o14sn4): theoretical value: c, 44.36；H, 6.01.Measured value: c, 44.40；H, 6.56.
ir(kbr, cm-1): 3126, 2959, 2926, 2859 v(c-h), 1638 vas(coo-), 1477 vas
(coo-), 642 v(sn-c), 464 v(sn-o).
1h nmr(cdcl3, 500 mhz), δ(ppm): 7.61, 7.12, 7.61(s, 12h, ar-h), 0.78-
1.73 (m, 72h, bu-h).
13c nmr(cdcl3, 125 mhz), δ(ppm): 163.20(coo), 147.58, 145.03, 116.63,
111.87(ar), 29.82, 27.56, 27.25, 27.11, 26.76, 26.71, 13.59, 13.56(bu).
119sn nmr(cdcl3, 186 mhz),δ(ppm): 194.21, 221.62.
Its crystallographic data: crystal belongs to monoclinic system, space group c2/c,a=4.4365 (3) nm,b=1.41495(10)
Nm,c=2.38869 (16) nm,α=90 °,β=121.6420 (10) °,γ=90 °,z=8, v=12.7658 (15) nm3,dc=
1.465mg·m-3,μ(moka)=1.601mm-1,f(000)=5664,1.67 ° of ＜θ25.00 ° of ＜, crystalline size: 0. 21 ×
0.20 × 0.18mm,r=0.0690,wr= 0.2016.
Test example:
The dibutyl tin furancarboxylic acid ester coordination compound of the stannum oxa- ring structure of the present invention, it is to pass through that its Anticancer Activity in vitro measures
Mtt experimental technique is realized.
Mtt analysis method:
With metabolism reduction 3- (4,5-dimethylthiazol-2-yl) -2,5-diarenyltetrazolium bromide it is
Basis.Succinate dehydrogenase in living cells mitochondria can make exogenous mtt be reduced to water-insoluble bluish violet crystallization first a ceremonial jade-ladle, used in libation
(formazan) and be deposited in cell, and dead cell no this function.Dimethyl sulfoxide (dmso) can dissolve the first a ceremonial jade-ladle, used in libation in cell,
Measure the optical density of characteristic wavelength with microplate reader, can indirectly reflect living cells quantity.
To measure the dibutyl tin furancarboxylic acid ester coordination compound pair of the stannum oxa- ring structure of embodiment 1 preparation using mtt method
Human lung carcinoma cell (nci-h460), human breast cancer cell (mcf7), the inhibitory activity of human liver cancer cell (hepg2).
Cell strain and cultivating system: nci-h460, mcf7 and hepg2 cell strain takes from American. tissue incubator (atcc).
With rpmi1640 (gibico company) culture medium containing 10% hyclone, in 5% (volume fraction) co2, 37 DEG C of saturated humidity trainings
Carry out In vitro culture in foster case.
Test process: test medicinal liquid (0.1nm-10um) is added separately in each hole according to the Concentraton gradient of concentration,
Each concentration sets 3 parallel holes.Experiment is divided into drug test group (being separately added into the test medicine of variable concentrations), matched group (only to add
Culture fluid and cell, are not added with testing medicine) and blank group (only adding culture fluid, be not added with cell and test medicine).By the orifice plate after dosing
It is placed in 37 DEG C, 5%co272h is cultivated in incubator.The activity of control drug measures according to the method for test sample.Cultivating
In orifice plate after 72h, every hole adds mtt40ul (being made into 4mg/ml with d-hanks buffer).After placing 4h at 37 DEG C, remove
Clear liquid.Every hole adds 150ul dmso, vibrates 5min, makes formazan crystallize dissolving.Finally, using automatic microplate reader in 570nm
The optical density in each hole is detected at wavelength.
Data processing: data processing uses graar pad prism version5.0 program, compound ic50By program
In there is the nonlinear regression model (NLRM) of s shape dose response be fitted obtaining.
With mtt analytic process to human lung carcinoma cell (nci-h460) cell strain, human breast cancer cell (mcf7) cell strain, people liver
Cancerous cell (hepg2) cell strain is analyzed, and measures its ic50Value, as shown in table 1, conclusion is result: from data in table,
The dibutyl tin furancarboxylic acid ester of the stannum oxa- ring structure of the present invention as cancer therapy drug, to human lung cancer, human breast carcinoma, human liver cancer
Active anticancer is higher, can be used as the candidate compound of cancer therapy drug.
The dibutyl tin furancarboxylic acid ester cancer therapy drug external activity test data of table 1 stannum oxa- ring structure
| Human lung carcinoma cell | Human breast cancer cell | Human liver cancer cell | |
| Cell strain | nci-h460 | mc-7 | hepg2 |
| ic50μm | 0.94 | 0.87 | 1.18 |
The dibutyl tin furancarboxylic acid ester coordination compound of the stannum oxa- ring structure of remaining embodiment preparation is with mtt method to human lung carcinoma cell
(nci-h460), the same test example of active anticancer method of testing of human liver cancer cell (hepg2) and human breast cancer cell (mcf7), surveys
Test result is essentially identical with table 1.
Claims (9)
1. the dibutyl tin furancarboxylic acid ester coordination compound of a kind of stannum oxa- ring structure, for the coordination compound of following structural formula (i):
(i)
In formula, r represents normal-butyl.
2. contain a kind of dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure as claimed in claim 1, it is infrared
Spectroscopic data: ft-ir (kbr, v/cm-1): 3126, 2959, 2926, 2859 v(c-h), 1638 vas(coo-),
1477 vas(coo-), 642 v(sn-c), 464 v(sn-o)；Its nuclear-magnetism modal data:1h nmr(cdcl3, 500 mhz), δ
(ppm): 7.61, 7.12, 7.61(s, 12h, ar-h), 0.78-1.73(m, 72h, bu-h)；13c nmr(cdcl3,
125 mhz), δ(ppm): 163.20(coo), 147.58, 145.03, 116.63, 111.87(ar), 29.82,
27.56, 27.25, 27.11, 26.76, 26.71, 13.59, 13.56(bu)；119sn nmr(cdcl3, 186 mhz),
δ(ppm): 194.21, 221.62.
3. the dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure as claimed in claim 1, wherein, described stannum oxygen
The dibutyl tin furancarboxylic acid ester coordination compound of heterocycle structure is crystal structure, and its crystallographic data is as follows: monoclinic system, space group
c2/c,a=4.4365 (3) nm,b=1.41495 (10) nm,c=2.38869 (16) nm,α=90 °,β=121.6420 (10) °,γ=90 °,z=8, v=12.7658 (15) nm3；There is the sn being constituted with stannum and oxygen atom in molecule2o2Planar four-element ring, three
Four-membered ring condenses formation four core stannum oxygen clusters trapezium structures using sn-o key atom for bridgehead atom, and the center of middle ring is molecule
Symmetrical centre, has two oxygen atoms, three terraced tin atoms of bridging respectively in ladder, bridging ladder stannum are former respectively separately two oxygen atoms
Son；The other two furan carboxyphenyls of ladder are utilized respectively its carboxyl oxygen atom and are become bond formed and its common chain with the tin atom of sn-o-sn chain
Hexa-atomic stannum oxa- ring structure.
4. the preparation method of the dibutyl tin furancarboxylic acid ester coordination compound of the stannum oxa- ring structure described in claim 1, its feature
It is, reaction vessel sequentially adds furancarboxylic acid, Dibutyltin oxide and etoh solvent in order, be 50 ~ 65 in temperature
8～24h is reacted under conditions of DEG C；Cooling, filters, and controls solvent volatilization crystallization, obtain water white transparency brilliant under conditions of 20 ~ 35 DEG C
Body, as dibutyl tin furancarboxylic acid ester.
5. preparation method as claimed in claim 4 is it is characterised in that the thing of described furancarboxylic acid, both Dibutyltin oxides
The amount of matter is than for 1:(1 ~ 1.05).
6. preparation method as claimed in claim 4 is it is characterised in that described etoh solvent consumption is every mM of dibutyl oxygen
Change stannum add 20 ~ 35 milliliters.
7. the dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure described in claim 1 has certain thermally-stabilised model
Enclose, can stable existence below 184 DEG C.
8. the dibutyl tin furancarboxylic acid ester coordination compound of stannum oxa- ring structure described in claim 1 answering in preparing cancer therapy drug
With.
9. the application described in claim 8, wherein said cancerous cell is pulmonary carcinoma, breast carcinoma, hepatocarcinoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610671064.3A CN106366112A (en) | 2016-08-16 | 2016-08-16 | Dibutylstannylfuran formate complex with heterocyclic oxotin structure, and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610671064.3A CN106366112A (en) | 2016-08-16 | 2016-08-16 | Dibutylstannylfuran formate complex with heterocyclic oxotin structure, and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106366112A true CN106366112A (en) | 2017-02-01 |
Family
ID=57878245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610671064.3A Pending CN106366112A (en) | 2016-08-16 | 2016-08-16 | Dibutylstannylfuran formate complex with heterocyclic oxotin structure, and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106366112A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1238336A (en) * | 1999-06-02 | 1999-12-15 | 山西大学 | Dibutyl tin compound of polynuclear heterocarboxyl acids and its synthesis |
| CN103304591A (en) * | 2013-06-17 | 2013-09-18 | 衡阳师范学院 | Dibutyltin 4-amino-3-methyl benzoate with tin-oxygen heterocyclic structure, and preparation method and application thereof |
-
2016
- 2016-08-16 CN CN201610671064.3A patent/CN106366112A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1238336A (en) * | 1999-06-02 | 1999-12-15 | 山西大学 | Dibutyl tin compound of polynuclear heterocarboxyl acids and its synthesis |
| CN103304591A (en) * | 2013-06-17 | 2013-09-18 | 衡阳师范学院 | Dibutyltin 4-amino-3-methyl benzoate with tin-oxygen heterocyclic structure, and preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| C. VATSA等: "Characterization of {[R2Sn(O2R’)]2O}2 (R=Me,Et,nPr and nBu;R’= thiophene and furan). X-ray crystal structure of {[nBu2Sn(O2CC4H3S)]2O}2", 《JOURNAL OF ORGANOMETALLIC CHEMISTRY》 * |
| MIN HONG等: "Coordination geometry of monomeric, dimeric and polymeric organotin(IV) compounds constructed from 5-bromopyridine-2-carboxylic acid and mono-,di- or tri-organotin precursors", 《JOURNAL OF MOLECULAR STRUCTURE》 * |
| 尹汉东等: "二{氧合-二[2-呋喃甲酸二苄基锡(IV)]}的合成、性质及晶体结构", 《有机化学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106279259A (en) | A kind of three (2 methyl 2 phenyl propyl) stannum 3,5 dinitrobenzoic acid ester coordination compound and preparation method and application | |
| CN106279253A (en) | A kind of double [three (2 methyl 2 phenyl) propyl group stannum] 5 nitroisophthalic acid ester coordination compounds and preparation method and application | |
| CN106188128B (en) | A kind of Tricyclohexyltin 2- naphthoate complex and the preparation method and application thereof | |
| CN107602606A (en) | A kind of three (adjacent bromobenzyl) tin salicylate complexs and preparation method and application | |
| CN106967109B (en) | One-dimensional two (o-chlorobenzyl) stannic chlorides 2- picolinic acid ester complex and the preparation method and application thereof | |
| CN106336427B (en) | A kind of 2- carbonyl -2- phenylacetic acid p-nitrophenyl formyl hydrazone two (2,4- dichloro benzyl) tin complex and its preparation method and application | |
| CN106366113A (en) | 2-oxo-propionic acid p-toluyl hydrazone di-2, 4-dichlorobenzyltin complex and its preparation method and use | |
| CN106366112A (en) | Dibutylstannylfuran formate complex with heterocyclic oxotin structure, and preparation method and application thereof | |
| CN107141315B (en) | A kind of di-n-butyl tin O-methoxy nicotinate complex and the preparation method and application thereof | |
| CN106336430B (en) | A kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone di-n-butyl tin complex and its preparation method and application | |
| CN105884817A (en) | Organic tin salicylate coordination polymer of trapezoid structure and preparation method and application thereof | |
| CN106279256A (en) | A kind of double [three (2 methyl 2 phenyl) propyl group stannum] 2,2 ' biphenyl dicarboxylic acid ester coordination compounds and preparation method and application | |
| CN106279257A (en) | A kind of dibutyl tin 2,4,5 trifluoro 3 methoxybenzoic acid ester coordination compound of stannum oxa-ring structure and preparation method and application | |
| CN106380480B (en) | A kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide complex and its preparation method and application | |
| CN106279714B (en) | A kind of 2,2 '-biphenyl dicarboxylic acid of Tricyclohexyltin ester coordination polymer and the preparation method and application thereof | |
| CN106317105B (en) | A kind of 2- carbonyl -2- phenylacetic acid p-nitrophenyl formyl hydrazone di-n-butyl tin complex and its preparation method and application | |
| CN106366118B (en) | A kind of 2- carbonyl -2- phenylacetic acid is to tert-butyl benzoyl hydrazone stannous phenide complex and its preparation method and application | |
| CN106220669A (en) | A kind of 2 carbonyl propionic acids to tert-butyl benzoyl hydrazone two to methyl-benzyl stannum coordination compound and its preparation method and application | |
| CN106279260B (en) | A kind of ALPHA-ketobutyric acid salicyloyl hydrazone di-n-butyl tin complex and its preparation method and application | |
| CN106279254A (en) | A kind of double (Tricyclohexyltin) 5 nitroisophthalic acid ester coordination compound and preparation method and application | |
| CN106220672B (en) | A kind of di-n-butyl tin complex of the ligand containing acylhydrazone and its preparation method and application | |
| CN106279258B (en) | A kind of dialkyl tin complex and its preparation method and application | |
| CN105837620A (en) | Chiral organotin carboxylate tris (2-methyl-2-phenyl ) propyl tin L-mandelate complex and preparation method and application thereof | |
| CN106366119A (en) | 2-carbonyl-2-phenyl acetic acid para methoxyphenyl carbonylhydrazone di-n-butyl tin complex and preparation method and application thereof | |
| CN105837619A (en) | Triphenyltin parahydroxybenzoate ester complex and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170201 |